HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Shanghai Pulse Medical Technology - The Industry, the Business and the Concerns

Will the Approval of Genuine Biotech's COVID-19 Oral Drug Change China's Zero-COVID Policy?

Pre-IPO Shanghai Chicmax Cosmetic - The Current Development Strategy Will Not Go Far

Taiwan Strait Dispute and China-US Tension: The Impact on China Healthcare

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Weimeizi (Guangdong) / Equity Capital Markets

<ul>
<li>WEIMEIZI develops the oral care market by means of large promotion and marketing so as to attract consumers, which helps Saky become one of the top brands in China.</li>
<li>However, with the layout of other long-lasting reputable brands and the entry of new brands, how to maintain the market share in fierce competition has become an important issue.</li>
<li>WEIMEIZI’s leading market position is not solid, unless it could create differentiated products and keep up with industry trends closely. </li>
</ul>


WEIMEIZI develops the oral care market by means of large promotion and marketing so as to attract consumers, which helps Saky become one of the top brands in China.
However, with the layout of other long-lasting reputable brands and the entry of new brands, how to maintain the market share in fierce competition has become an important issue.
WEIMEIZI’s leading market position is not solid, unless it could create differentiated products and keep up with industry trends closely. 


Pre-IPO Weimeizi (Guangdong) - The Market Position Is Not Solid